Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL774435 | 0.89 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL6495440 | 0.89 | ALDH1A1 (0.48) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1691179 | 0.89 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2196345 | 0.89 | KDM4E (0.39) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1613295 | 0.86 | USP2 (0.50) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL23151890 | 0.82 | ALDH1A1 (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL4282842 | 0.82 | ALDH1A1 (0.46) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1035150 | 0.80 | ALDH1A1 (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL708723 | 0.80 | SCN9A (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL15313206 | 0.80 | USP2 (0.44) | KDM4EUSP2ALDH1A1LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2020-04-14 | — | — | US | disclosed |
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| CN-107614501-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-12 | — | — | US | disclosed |
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-7214686-B2 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | ABBVIE INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006069196-A1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2006-06-29 | — | — | WO | disclosed |
| US-6969712-B2 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-29 | — | — | US | disclosed |
| WO-2004108668-A2 | ALPHA-7 NEURONAL NICOTINIC RECEPTOR LIGANDS: COMPOSITIONS AND METHODS OF USE | TARGACEPT, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. | 2004-11-04 | — | — | US | disclosed |
| US-20040044056-A1 | Benzimidazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-04 | — | — | US | disclosed |
| EP-1342717-A1 | BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | KDM4E 3896/4885USP2 902/4885ALDH1A1 380/4885 |
| US-10618898-B2 | Hydroxyl purine compounds and use thereof | PNP, PDE7A, PDE2A | KDM4E 3896/4885USP2 902/4885ALDH1A1 380/4885 |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | KDM4E 3141/4885USP2 4251/4885ALDH1A1 639/4885 |
| US-20070037801-A1 | {1-[(1-methylpiperidin-2-yl)methyl]-1H-indol-3-yl}(2,2,3,3-tetramethylcyclopropyl)methanone toluenesufonic acid salt; selectively target cannaboid B2 receptors; analgesics for both nociceptive and neuropathic pain; side effect reduction; immunology modulators; antiinflammatory agents; neuroprotectants | CNR2, CNR1, TRPV1 | KDM4E 3554/4885USP2 3924/4885ALDH1A1 1901/4885 |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | COMT, SLC6A3, PARK7 | KDM4E 3536/4885USP2 2042/4885ALDH1A1 1466/4885 |
| US-20040044056-A1 | Benzimidazole derivatives | GPR119, OPRL1, INSR | KDM4E 2367/4885USP2 4219/4885ALDH1A1 1851/4885 |
| US-20170291905-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT6 | KDM4E 238/4885USP2 1833/4885ALDH1A1 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.